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A B S T R A C T
The coronavirus disease 2019 (COVID-19) pandemic has produced a world-wide collapse of social and economic
infrastructure, as well as constrained our freedom of movement. This respiratory tract infection is nefarious in
how it targets the most distal and highly vulnerable aspect of the human bronchopulmonary tree, specifically,
the delicate yet irreplaceable alveoli that are responsible for the loading of oxygen upon red cell hemoglobin for
use by all of the body's tissues.
In most symptomatic individuals, the disease is a mild immune-mediated syndrome, with limited damage to
the lung tissues. About 20% of those affected experience a disease course characterized by a cataclysmic set of
immune activation responses that can culminate in the diffuse and irreversible obliteration of the distal alveoli,
leading to a virtual collapse of the gas-exchange apparatus.
Here, in Part I of a duology on the characterization and potential treatment for COVID-19, we define severe
COVID-19 as a consequence of the ability of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
to trigger what we now designate for the first time as a ‘Prolific Activation of a Network-Immune-Inflammatory
Crisis’, or ‘PANIC’ Attack, in the alveolar tree. In Part II we describe an immunotherapeutic hypothesis worthy of
the organization of a randomized clinical trial in order to ascertain whether a repurposed, generic, inexpensive,
and widely available agent is capable of abolishing ‘PANIC’; thereby preventing or mitigating severe COVID-19,
with monumental ramifications for world health, and the global pandemic that continues to threaten it.
1. Introduction
Rarely before has civilization been confronted with such a formid-
able enemy, one that is wholly invisible, often resulting in no identifi-
able symptoms, and yet, it is highly transmissible and the cause of a
rapidly disseminated viral pandemic. The monumental penetrance of
this microbe has culminated in the virtual collapse of nearly every
endeavor which entails the close proximity of one human being to
another. The majority (~80%) of those infected by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) experience a mild to
moderate flu-like respiratory tract illness, Coronavirus Disease 2019
(COVID-19). The minority of those infected (~20%) experience a se-
vere disease course that can result in death [1]. Without equivocation,
SARS-CoV-2 is endowed with two fundamental characteristics, which
when combined together, can foment incontrovertibly one of the most
ominous semiologic courses of illness recognized in modern medicine.
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Firstly, SARS-CoV-2 targets its entry receptor, through which it
mediates its viral tropism. Specifically, the SARS-CoV-2 surface glyco-
protein, ‘spike’, binds to the angiotensin converting enzyme (ACE-2-r)
receptor [2], which is broadly distributed throughout the body. This
Coronavirus binds with particular predilection for the extreme terminus
of our bronchopulmonary anatomy, especially the alveolar gas-ex-
change apparatus, which is responsible for the continuous loading and
subsequent delivery of oxygen to all of the tissues of the body.
Secondly, while the majority of COVID-19 patients will mount an
appropriate, coordinated, and highly regulated host-immune-response
to the etiologic agent, approximately 20% of infected individuals shall
instead be subjected to the consequences of the ability of SARS-CoV-2 to
trigger a ‘prolific activation of a network-immune-inflammatory crisis’,
or ‘PANIC’ Attack. The latter host response involves the widely and
indiscriminantly activated limbs of the entire immune response net-
work, which results in a confluence of convergent immune effector
elements (Table 1). Targeted sites include the most delicate and vul-
nerable of our life-sustaining circuitries, resulting in the cataclysmic
obliteration of lung alveoli by exceeding a damage threshold for these
indespensible and slow to repair gas-exchange structures – often ex-
ceeding the repair and replacement mechanism leading to ultimate end
stage organ damage and potentially death.
Overwhelming the limiting threshold for damage to our 600 million
alveoli has been associated with the abrupt collapse of circulatory
oxygen saturation and delivery, which becomes refractory to any in-
tervention, thereby presaging multiorgan hypoxic-ischemia and death.
The designation of severe COVID-19 can be characterized by a number
of risk factors and clinical manifestations that implicate the nervous
system as either a target tissue of the disorder's pathophysiologic un-
derpinnings, or as playing a fundamental role in the compromise in the
fidelity of centrally integrated regulatory mechanisms which both
‘sense’ and respond to alterations in respiratory metrics. To illustrate
one such pathway, trace the partial pressures of oxygen and carbon
dioxide as codified by the sensing apparatus in the carotid bodies, and
transmitted via the nerves of Hering (small branch of the glossophar-
yngeal nerve), to the solitary tract and nucleus localized to the caudal
medullary tegementum. The integrity of the complex connectivity of
this circuitry must be maintained in order to achieve its goal of reg-
ulating all functions of the respiratory system to maintain oxygen sa-
turation and delivery to ensure continuous organ tissue viability.
A principal goal herein is to confirm both face and construct validity
for the principle of this new definition for a poorly coordinated and
dysregulated sequence of coincidentally activated limbs of the immune
network (i.e. PANIC), and the consequences of such upon the primary
target tissue for an infection as virulent and strategically ominous as
SARS-CoV-2. Further, given the prolific immune activation associated
with microbial-induced ‘PANIC’, in Part II of this publication, we ad-
vance the hypothesis that effective therapy should thereby provide a
pleiotropic strategy commensurate with the range of the immune sys-
tem's diversity of activation by SARS-CoV-2.
SARS-CoV-2 triggers PANIC which the authors find reminiscent of
phenomenonlogy which we have previously identified (and published
in the Journal of the Neuological Sciences) as ‘monumentally severe
central nervous system (CNS) inflammatory syndromes’ that were as-
sociated with multiple sclerosis (MS), neuromyelitis optica (NMO), and
Sjogren's syndrome myelitis; all of which were refractory to conven-
tional, even intensive, immunotherapy. The successful rescue inter-
vention reported utilized the application of high-dose methotrexate
with leucovorin rescue (HDMTX-LR), an intensive and highly pleio-
tropic anti-inflammatory strategy [3]. Since then, we have treated a
broadening diversity of other causes that we believe to be variants of
‘PANIC’, including other post-infectious (e.g. post-adenovirus) [Fig. 1]
and post-vaccinal (e.g. post-dTap) encephalomyelitides [Fig. 2].
Though classically defined as nuances of acute disseminated en-
cephalomyelitis (ADEM), they were, however, recalcitrant to conven-
tional immunotherapy, but were stereotypically abolished utilizing our
HDMTX-LR treatment strategy.
2. COVID-19: it began in China
In December 2019, in Wuhan, Hubei Province; China reported an
outbreak of a highly communicable viral infection. Initially, it was re-
ported to be a form of treatment resistant pneumonia. Subsequently, it
was recognized that the etiologic agent was, in fact, a novel
Coronavirus. Humans had never before been exposed to this infectious
agent, and carried no immunity to prevent its spectrum of clinical
manifestations ranging from mild, even asymptomatic courses, to
Table 1
Prolific Activation of a Network-Immune Inflammatory Crisis [PANIC]:A New
Pathophysiologic Signature for Severe COVID-19.
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severe, even fatal disease, with a particular targeting of the respiratory
tract [4]. SARS-CoV-2, the etiological agent of COVID-19, has now in-
fected patients across 210 countries and terratories, and has fomented a
catastrophic global crisis, associated with medical, economic, and
psychosocial ramifications of immense magnitude.The World Health
Organization declared the outbreak of SARS-CoV-2 as a Public Health
Emergency of International Concern on January 30, 2020 [5–10].
SARS-CoV-2 transmission is easily disseminated via aerosolization
and droplets, with recent evidence suggesting that even non-amplified
speech can effectively project oropharyngeal derived material con-
taining virus to become airborne and capable of traveling distances
typical for standard conversation [11,12]. Unlike the antecedent epi-
demics of SARS-CoV and Middle East respiratory syndrome coronavirus
(MERS-CoV), SARS-CoV-2 originated in Wuhan, Hubei Province, China
and subsequently and rapidly disseminated globally confirming its
designation as a pandemic. This ultimately led the world to ‘shelter in
place’, because without an effective therapy, the best chance to quell
the perpetual dissemination of infectivity, is to avoid transmissible
contacts. Given the striking transmissibility of SARS-CoV-2, in con-
junction with the large proportion of both mildly affected and asymp-
tomatic individuals harboring infection, both ‘shelter in place’, together
with widespread availability of testing to confirm infection, as well as
Fig. 1. A) Axial FLAIR-weighted MRI prior to HDMTX-LR, B) Axial FLAIR-weighted MRI after HDMTX-LR for adenovirus triggered PANIC.
Fig. 2. A) Axial FLAIR-weighted MRI prior to HDMTX-LR, B) Axial FLAIR-weighted MRI after HDMTX-LR for a 3rd trimester vaccinal (dTap) triggered PANIC-
associated encephalomyelitis.
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active immunity, represents our best strategy to prevent further dis-
semination and also to identify newly infected cases as early as possible.
3. COVID-19-associated clinical manifestations
According to currently available data, at the time of submission of
this article, approximately 80% of individuals who become infected
with SARS-CoV-2 will experience a relatively mild, short duration
syndrome; with many being wholly asymptomatic. The other 20% of
SARS-CoV-2 infected patients will progress to exhibit a severe variant of
this infection characterized by fever and a respiratory tract ‘flu-like’
illness. They may suffer from fever, cough, pharyngitis, headache,
dyspnea, myalgias, chest pain, nausea, vomiting, confusion, and inter-
estingly, anosmia and dysgeusia in a small albeit conspicuous propor-
tion of patients (~5%) [11,13,14]. This severe disease transitions to an
accelerated course of predominant respiratory deterioration, requiring
intensive multidisciplinary management, including respiratory support
with pressure ventilation. Addtionally, there is a high predilection for a
diverse constellation of multi-organ derangements, with the most se-
verely affected individuals exhibiting multi-organ failure [15].
In the initial Wuwan cohort, characteristic chest CT findings were
identified in 98% of 41 patients, with involvement of both lungs, and
features consistent with the ‘so-called’ ground glass opacifications. Of
those patients that deteriorated, most required intensive care unit (ICU)
management, while paradoxically exhibiting a resolution of lung con-
solidations in comparison to those not requiring admission to the ICU
[4]. The median duration (in days) between the onset of symptoms and
the passing of clinically relevant and prognostic milestones of the se-
verely affected was also documented in the Wuhan patients. Specifi-
cally, admission to hospital (7 days), onset of dyspnea (8 days), diag-
nosis of acute respiratory distress syndrome (ARDS) (9 days), admission
to ICU (10.5 days), and mechanical ventilation (10.5 days). The timing
from hospital admission to diagnosis of ARDS was also reported to be as
short as two days, at which point such patients had a mortality rate of
15% [4].
Risk factors associated with the designation of severe COVID-19
included male gender, advanced age, and pre-existing co-morbid con-
ditions, especially hypertension, diabetes, morbid obesity, and smoking
[16]. The clinical semiology for the most severly affected patients was
most commonly comprised of interstitial pneumonia with rapid tran-
sition to ARDS, septic shock, and evidence of the liberation of acute
phase reactants in conjunction with macrophage activation. Ad-
ditionally, serum elevation of C-reactive protein (CRP) and D-dimer,
were correlated with liver dysfunction and hyperferritinemia, labora-
tory findings which can be accompanied by the syndrome of dis-
seminated intravascular coagulation (DIC), as well as hypercoagulable
derangements, which can lead to stasis, clot formation, and ultimately
altered or abolished blood flow dynamics within the alveolar capillary
network [4].
4. Neurological manifestations of SARS-CoV-2 induced COVID-19
In the severely ill COVID-19 patients, front-line healthcare workers
have been largely preoccupied with providing adequate life-support,
prioritizing the integrity of the respiratory and circulatory systems, and
keeping blood oxygen saturation above the threshold where end organ
damage ensues. In those with a rapid transition from minor symptoms
to urgent admission to an ICU, the majority will require ventilator
support, along with continuous observation and repeated assessments
of each of the major body systems. Given the potential for any given
COVID-19 patient to abruptly deteriorate, clinical management man-
dates a systematic sequence of intensive care measures and protocols
principally aimed at avoiding a period of hypoxic ischemia. It is for this
reason, at least in part, that our understanding of the neurologic
manifestations of COVID-19 lags behind our understanding of the more
omnipresent and existential concerns that are associated with patients
so severely affected by this infection.
The ICU priorities can hinder the ability of any subspecialist to carry
out their assessments, as well as limit recommendations for those in-
vestigations that require the patient to leave the ICU setting (e.g. as
with the performance of imaging studies including CT and MRI). Each
departure for additional testing must be cautiously weighed against the
risks and benefits of such investigations. Despite these limitations, we
have now gained some insights into complications of SARS-CoV-2 in-
fection that target the CNS and peripheral nervous system (PNS)
[14,17–23].
COVID-19 neurological manifestations are thought to result from
indirect and direct actions of SARS-CoV-2 on the CNS and PNS. Indirect
actions of the virus are related to injury to peripheral organs, such as
the lungs, kidneys, liver, and heart. For example, myocardial and lung
invasion by SARS-CoV-2 could result in cardiac failure and arrhythmias,
which could in turn increase the secondary risk of stroke or pulmonary
embolism as a result of stasis within the chambers of the heart [24–27].
Alternatively, SARS-CoV-2 could directly damage the brain and spinal
cord either via hematogenous spread or via neural propagation into the
CNS [28].
Other coronaviruses, such as SARS-CoV-1 and human coronavirus
OC43 have been shown to enter into the nasal passages and spread to
the olfactory bulb, pyriform cortex, dorsal nucleus of the rafe in the
brainstem, and spinal cord [29,30]. Of note, ablation within the ol-
factory pathway can prevent the neural spread of MHV coronavirus in
animals [31]. Cellular entry of SARS-CoV-2 occurs through the ACE-2-r.
Interestingly, ACE-2-r is expressed widely in the CNS within neurons,
motor cortex, hypothalamus, thalamus, and brainstem [32–37].
The physical distribution of ACE-2-r in the brain could account for
some of the clinical symptoms observed in patients. For example, direct
neuronal injury within the brainstem cardiorespiratory centers in the
medulla, could explain the peak disease cardiovascular and respiratory
complications in COVID-19 patients [30]. In addition, anosmia and
ageusia in COVID-19 patients may be related to viral entry through
ACE-2-r within the olfactory system or within the hypothalamus.
A recently published retrospective observational case series focused
upon the neurologic manifestations of COVID-19 from Wuhan China,
and included 214 consecutive hospitalized patients with laboratory-
confirmed diagnosis [14]. This analysis showed that approximately
60% of patients were designated as having mild disease, with the re-
mainder characterized as having severe infection, defined with respect
to their respiratory status. Approximately 36% of the cohort exhibited
neurological manifestations, with those designated as having more se-
vere disease being more likely to significantly harbor comorbid condi-
tions with hypertension being most common, as well as being sig-
nificantly less likely to present with the more typical respiratory
symptoms (at least at presentation) of COVID-19, such as cough in the
context of fever [14].
Patients most likely to present with neurologic symptoms tended to
be significantly older, and also afflicted with severe infection, with the
majority of neurologic features occurring in the CNS (e.g. stroke, po-
tentially influenced by features of a thrombotic microangiopathy, with
or without cardiac disease, impaired consciousness, headache, dizzi-
ness, anosmia, dysgeusia, etc.), versus the PNS. These same individuals
were also significantly more likely to present with elevated D-dimer
levels (reminiscent of a consumptive coagulopathy, such as DIC), along
with multiorgan derangements, like hepatic transaminitis, renal in-
sufficiency signified by rising blood urea nitrogen (BUN) and creatinine
levels, and serum elevation of muscle creatinine kinase levels. It has
been established that inflammatory disease tips the coagulation cascade
to a ‘pro-coagulant state’. This has been observed in neuroinflammatory
disorders, including MS and its animal counterpart, experimental au-
toimmune enchephalomyelitis (EAE) [38].
Some of the patients presented with neurologic features, in the
absence of typical COVID-19 symptoms, and tested negative by chest
CT imaging and by COVID-19 blood testing. Days later, these
E.M. Frohman, et al. Journal of the Neurological Sciences 415 (2020) 116936
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individuals manifested the features of cough and sore throat, in con-
junction with lymphopenia and the evolution of characteristic ‘ground-
glass’ opacification lesions demonstrated on repeat chest CT. Indeed,
their SARS-CoV-2 infections were later corroborated by nucleic acid
testing [14]. Alternatively, those patients presenting with PNS features
did not significantly correlate with any laboratory assessments. Di-
chotomizing patients categorically into severe versus non-severe
COVID-19 did not significantly correspond to the presence or absence of
PNS involvement.
5. Virology of SARS-CoV-2 infection
SARS-CoV-2 represents the third and most-widespread Coronavirus
zoonosis, preceded by SARS-CoV and MERS-CoV. All three of these
zoonoses are believed to have originated in bats and transitioned to
humans via intermediate hosts [39]. The Coronavirus' namesake is
derived from its structural ‘crown-like’ appearance. The virus is com-
posed of a positive sense single stranded RNA physically associated
with a nucleocapsid, within a phospholipid bilayer, with the envelope
decorated with externally projecting spike glycoproteins [40]. The viral
spike interacts with its receptor, ACE-2-r, on susceptible target cells to
facilitate entry and viral replication [41].
With the identification of the ACE-2-r receptor as the binding site
for SARS-CoV-2 spike protein and its corresponding tropism, there was
a groundswell of concern that ACE inhibitors and/or angiotensin re-
ceptor blockers would confer an increased risk upon infected patients.
However, patients with COVID-19, who were treated with ACE-in-
hibitors or angiotensin receptor blockers, continue to derive both car-
diovascular and renal protection, and in fact, the discontinuation of
these agents might be harmful [42].
6. ‘Irrational exuberance’ of immune-mediated inflammatory
networks
Evidence is rapidly mounting to suggest that the severe lung damage
in COVID-19 is the result of both the activation of diverse limbs of host
immune networks, in conjunction with exaggerated activities of each of
these responses to SARS-CoV-2 [Fig. 3]. To more accurately account for
viral induction of the coincident confluence of converging in-
flammatory cascades, and for differentiation of the characteristics of the
immune-mediated responses in those designated to have mild versus
severe COVID-19 disease, we have, for the first time to our knowledge,
coined an acronym that reflects the severe magnitude and cataclysmic
evolution of the severe variant of COVID-19: In essence; the PANIC
Attack.
7. The ominous target for the SARS-CoV-2 ‘Triggered’ PANIC
attack
The terminus of the broncho-pulmonary tree is the most important
target of SARS-CoV-2, and is comprised of a duct system consisting of
about 100 alveolar sacs, each composed of 20–30 alveoli. All totaled,
there are some 600 million alveoli in the lungs [43]. Each individual
alveolar membrane is 1-cell-thick and necessitates an intimate and tight
juxtaposition of the alveolar epithelium with that of the pulmonary
capillary endothelium, also with the thickness of a single cell. The
single-cell arrangement, and ultra-tight juxtaposition of the capillary
anatomy with that of the alveolar epithelium, constitutes an ideal ar-
chitecture for the principal goal of pulmonary physiology, the loading
of oxygen onto red cell hemoglobin and the expulsion of CO2 from the
lungs into the ambient air [Fig. 3].
The convergent inflammatory cascades focused upon this highly
delicate and vulnerable bronchopulmonary gas-exchange scaffolding is
what makes this Coronavirus so ominously dangerous (Table 1). A
further challenge relates to the limited window of opportunity to ther-
apeutically intervene before the obliteration of a corpus of alveoli, from
which survival is no longer feasible. Many who have succumbed to
COVID-19, have done so while being carefully managed on pressure
ventilation, with adequate respiratory rate (whether patient or venti-
lator triggered), and continuous delivery of oxygen, commensurate
with optimization and persistency of 02 saturation kinetics. The addi-
tion of positive end expiratory pressure (PEEP) ensures that the
bronchopulmonary terminus remains patent to facilitate effective gas
diffusion. Another dividend of pressure ventilation is that it contributes
to the process of effective pulmonary toilet, now referred to as Pul-
monary Hygiene, and involves the use of medications, devices, and/or
maneuvers, which are principally aimed at optimizing mucus clearance
mechanisms [44].
Without effective mucus clearance, there is a greater chance of or-
ganization of inspisated mucus combined with protein-rich fluid, pro-
duced secondary to localized inflammatory activities, material from the
immune-mediated debris-field (including that from the exfoliation of
destroyed alveoli epithelial cells), and trapped microbial material,
which normally enters the lung with ambient airflow, these microbes
include such species as MRSA and other pharengeal and enteric species.
Despite the capabilities of state of the art pressure ventilation devices,
many COVID-19 patients who fail to wean off ventilator support exhibit
a precipitous deterioration, heralded by the abrupt onset of oxygen
desaturation, despite full mechanical support and control over the de-
livery of high oxygen concentration in conjunction with maximized
PEEP.
While the obliteration of a threshold level of alveoli may be re-
sponsible for the observation of catastrophic collapse of the gas-ex-
change apparatus, it has been suggested that SARS-CoV-2 may dis-
seminate into the caudal medullary tegmentum and inflict damage
upon the CNS cardiorespiratory centers, such as the solitary tract and
nucleus. This Center is endowed with the ability to sense and respond to
alterations in the partial pressures of CO2 and O2, via information
transmitted by the carotid bodies through the nerves of Hering, bran-
ches of the glossopharyngeal cranial nerve IX [13,45,46].
These observations suggest that there needs to be urgent interven-
tion capable of uncoupling the unchecked inflammatory PANIC tar-
geting the gas-exchange anatomy of the lung. Once a critical disease
burden has destroyed a sufficient number of alveoli, further manage-
ment is futile. Such patients can no longer saturate hemoglobin with the
minimal threshold of oxygen in order to sustain the viability of the
body's primary organ systems.
For instance, protracted periods of hypoxic-ischemia will have
nearly instantaneous adverse effects upon those systems requiring the
highest supply to demand bioenergetic signatures, such as the brain,
heart, kidneys and liver.
Other medical manifestations of the COVID-19 infection include a
vasculitis with risk of progressing to gangrene [47–49]. Some patients
have evidence of spleen destruction and diffuse atrophy of lymph
nodes, and their associated regional chains [47]. Others can harbor
evidence of anti-phospholipid, anti-cardiolipin, and anti-β2-glycopro-
tein antibodies, each of which might signify the presence of a corre-
sponding syndrome, with ramifications that only serve to intensify the
demands upon patient management, and those responsible to deliver it
[50].
8. The pathophysiology of the SARS-CoV-2 triggered PANIC-attack
8.1. Role of complement in the SARS-CoV-2-triggered PANIC-attack
SARS-CoV-2 can enter cells within the lungs via the endosomal
pathway, or conceivably by fusion mechanisms that might also allow
for the development of syncytia [Fig. 3]. Destruction of alveolar cells
expressing ACE-2-r by SARS-CoV-2 could theoretically be orchestrated
by post-viral replication cell bursting, or by antigen-antibody complex
triggering complement-dependent cytotoxicity (CDC) via activation of
the complement pathway [51,52]. Activation of the complement
E.M. Frohman, et al. Journal of the Neurological Sciences 415 (2020) 116936
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pathway would result in the C3a and C5a fragments acting as ana-
phylatoxins, through increasing the leakage of the capillary beds, and
chemotaxins, serving to recruit neutrophils, monocytes, macrophages,
and eosinophils into the target tissue. Upon arrival, these cells would
release their immune effector mediators, including free radicals and
reactive oxygen species (such as superoxide). Alternatively, distal
activation of the complement pathways involving C5 convertase leads
to the assembly of the C5b-C8 coordinated membrane attack complex
(MAC) and the subsequent traversal of C9 into the MAC channel and
across the cell membrane (i.e. the alveolar epithelium), leading to os-
motic derangements culminating in cell death [Fig. 3].
In order to ascertain the role played by the complement system in
(caption on next page)
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the pathobiology of COVID-19, a recently reported case series char-
acterized the recovery of four ICU patients with severe COVID-19 as-
sociated pneumonia or ARDS, in response to eculizumab, an antibody
against C5 convertase, which ultimately prevents the assembly of MAC,
and thereby CDC [53].
Eculizumab has been FDA approved for a number of conditions
where pathogenic antibody is complement fixating, and upon engage-
ment with its antigen, there occurs the initiation of the assembly se-
quence involving C5beC8, that ultimately culminates in the formation
of the MAC, through which C9 can then traverse and breach the in-
tegrity of the cell membrane sufficient to promote cell death. The
conditions that have been shown to be effectively treated by ecluli-
zumab include hemolytic uremic syndrome (HUS), paroxysmal noc-
turnal hemoglobinuria (PNH), myasthenia gravis, and most recently
AQP4+ neuromyelitis optica spectrum disorder (NMOSD) patients [54].
Administration of eculizumab early in the disease course may ulti-
mately shed light on the role of complement-dependent injury path-
ways on the disease burden in the distal bronchopulmonary circuit. The
diverse spectrum of innate and adaptive immune activation, ignited by
the SARS-CoV-2 agent, is compositionally part of our ‘PANIC’ Attack
hypothesis.
We hypothesize that the early presence of both IgM and IgG directed
to spike is germane to the activation of complement within the lung by
the classical pathway, which is principally triggered by the recognition
of antigen-antibody complexes. The latter of which must be of appro-
priate isotype in order to ‘fix’, and thereby activate, the classic
complement cascade [Fig. 3]. The alternate and lectin activated com-
plement cascades are also likely ignited in the lung of severely affected
COVID-19 patients. The former can be activated by either C3b or via
contact with surface epitopes, such as those liberated by damaged cells,
while the latter pathway is antibody-independent and becomes acti-
vated when mannose binding lectin (MBL) binds to glycosylated moi-
eties upon the surface of pathogens.
Upon convergence with the serine esterase sequence activation of
the complement cascade, all three paths ultimately lead to cleavage
products, such as the anaphylatoxins and chemotaxins, C3a, C4a, and
C5a, which can increase vascular permeability in concert with pro-
moting the redistribution of circulating neutrophils, eosinophils,
monocytes, and macrophages into the site of the tissue localization
where the complement cascades were activated [55,56]. Upon their
arrival, these leukocytes can elaborate a number of highly potent and
injurious immune effector elements (i.e. free radicals, superoxides, etc),
which together further contribute to both the process of attempted
neutralization of the immune challenge, which is SARS-CoV-2, as well
as potentially fomenting a considerable amount of damage to the sur-
rounding host tissue structure (i.e. bystander damage) [57,58]. The
anaphylatoxins C3a and C5a further intensify and perpetuate organ
tissue damage in COVID-19 via escalation of IL-1, IL-6, TNFα, as well as
mast cell histamine degranulation [59–61].
Fig. 3. Here we present the principal target of SARS-CoV-2, the most distal extent of the bronchopulmonary tree; the alveoli and its complex architecture and tight
juxtaposition with respect to the capillary terminals of the most distal pulmonary arteries and pulmonary veins. A) We present the components of SARS-CoV-2. Note
that the virion has a positive single strand RNA, which is enclosed within a sphere delimited by membrane bilayers of phospholipid. Projecting out of the virion is the
spike protein; the most important component, given that SARS-CoV-2 tropism is contingent upon the binding of spike to its entry receptor, the angiotensin converting
enzyme 2 receptor (ACE-2-r). B) Demonstrates a pull-out in order to reveal the normal grape-like cluster arrangement of lung alveoli (on the left), in contrast to C) the
irregular ‘deflated’ appearance of this terminal anatomic specialization that occurs in severe COVID-19 D) Represents the indivisible functional unit for gas-exchange,
comprised of a single cell thick lining of epithelium. However, an added level of complexity relates to the differentiation of the cellular subtypes of the alveolar
epithelial cells with the type I pneumocyte representing the principal cell responsible for gas exchange; the type II pneumocyte secretes surfactant, crucial for
reducing alveolar surface tension, which prevents alveolar collapse; and the type III pneumocyte or alveolar macrophage (aka ‘dust cells’) which are mobile and serve
as a kind of ‘vacuum cleaner’ capable of removing a wide diversity of contaminants and microbial elements in order to minimize interference with ‘clean’ gas-
exchange. Inside the alveolus we illustrate the aerosolized entry of SARS-CoV-2, and some of the immune elements which have trafficked to this site, secondary to
immune network activation by the virus. This includes the accumulation of macrophages, mast cells, polymophonuclear neutrophils (PMNs), along with the cellular
release of each cell's effector elements, such as cytokines, chemokines, free radicals, and reactive oxygen species. On the outer circular perimeter of the figure, we
have magnified the circumferential organization of the alveolar epithelium in order to illustrate the distinctive mechanisms which collectively represent the SARS-
CoV-2 triggered ‘prolific activation of a network immune-mediated, inflammatory crisis (‘PANIC’). E) We illustrate the sentinel step in viral entry and replication, vis
a vis binding of the spike protein on the virion surface to ACE-2-r on the surface of the alveolar epithelium. Subsequent to this binding interaction is the entry of the
virus into the epithelium via the endosomal pathway, culminating in the release of viral RNA in preparation for replication and eventual release of new virions,
thereby perpetuating an amplification of the viral lifecycle and the corresponding acceleration in the destruction of lung alveoli, until a threshold burden of disease is
established, beyond which the body's continuous demand for oxygen can no longer be achieved, at which point bioenergetic collapse occurs and heralds in the rapid
demise and ultimately death of the patient. F) A distinctive facet of the PANIC Attack is illustrated where an infected cell has entered a terminal phase, apoptosis. This
cell-death sequence involves the massive release of cytokines and chemokines at the termination of the cell's viability, and is referred to as pyroptosis. G) We illustrate
adaptive immune mechanisms triggered by the virus, which set into motion the development of both humoral (antibody generation), as well as cellular (with
phenotypes determined by the preferential synthesis and release of cytokine and chemokine elements, which we can dichotomize into a categorical scheme of pro-
inflammatory vs anti-inflammatory or immunoregulatory profiles) immune activities. Such processes commence with the organization of the immunologic ‘synapse’,
which includes processed antigen (e.g. viral epitope; such as the SARS-CoV-2 peptide) coupled to major histocompatibility complex II proteins in an antigen
presenting cell (such as a macrophage, dendritic cell, or B cell), then shuttled to the cell surface where this complex interacts with a T cell receptor; and the
subsequent activation of response priming mechanisms. Priming can result in T cell mediated activities, principally via cytokine and chemokine networks, whereas
humoral or B cell networks involve a complex array of activities which commence with somatic hypermutations within the immunoglobulin gene complex, which
promotes the development of affinity (a means by which an antibody can bind to its cognate antigen) and avidity (a measure of the binding strength between an
antibody and the antigen) maturation, followed by class switching from the acute IgM subtype to the convalescent and memory IgG phenotype. H) We illustrate
alveolar epithelial membrane, albeit with a segment of the SARS-CoV-2 membrane integrated at the cell surface. In this case, we can observe that the cell membrane
expresses spike protein. However, rather than interacting with ACE-2-r, the PANIC Attack process has generated antibodies which bind to spike protein giving rise to
either macrophage Fc receptor binding to the Fc portion of the anti-spike antibody and clearance via the reticuloendothelial system (RES), or activation of the
complement fixation site on the anti-spike antibody which sets into motion a series of immune activities, which can foment further damage to the alveolar gas
exchange apparatus. Activation of the lectin complement pathway, the alternative pathway (via contact with surfaces, including dead cellular debris), and the
classical complement pathway all converge to activate a series of serine esterases, leading to the liberation of C3a and C5a, which serve as anaphylatoxins and
chemotaxins promoting innate immune activities such as the migration of cellular elements (e.g. neutrophils, monocytes, macrophages, and eosinophils) into the
alveoli, whereupon their arrival, their effector species (super oxides, free radicals, histamine, etc) can be released and damage the delicate architecture of the gas
exchange apparatus. I) We illustrate how complement system activition also involves the coordination between C5b-C8 in the assembly of the membrane attack
complex (MAC), which contains a central channel, whereby C9 traverses the MAC and perforates the epithelial cell membrane culminating in cell death and
ultimately exfoliation; a cataclysmic step in the destruction of the integrity of the alveoli, and failure of localized gas exchange.
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8.2. Role of the cytokine ‘Storm’ in SARS-CoV-2 triggering of the PANIC-
attack
While IL-6 is elevated in about 33% of mild COVID-19 patients, 76%
of severely affected patients exhibit elevation of this pro-inflammatory
cytokine. In fact, COVID-19 patients characterized as having severe
disease have corresponding escalations of IL-6, TNF-α, IL-2, MCP-1,
MIP-1A, IL-10, IL-7, and G-CSF, especially in ICU patients [4,62]. Fur-
ther, evidence of cytokine release syndrome (CRS) or ‘storm’ was con-
firmed by an escalation in IL-6 levels [63] in conjunction with in-
adequate levels of the negative regulatory suppressor of cytokine
signaling 3 (SOC 3) [64].
Perhaps the laboratory finding of greatest conspicuity in those with
confirmed COVID-19 is lymphopenia, posited to potentially represent
the consequence of the broadening of SARS-CoV-2 distribution and
apoptosis, the terminal phenomenon of viral infection [65,66]. An al-
ternative explanation is that the lymphopenia may be due to a cortisol
burst from stress. The sequestration of lymphocytes into the lungs may
also be a feasible hypothesis for the circulating lymphopenia (let's recall
that only 3–5% of the body's mononuclear cells are in circulation at any
given time). Despite the lymphopenia, widespread lymphocyte activa-
tion is a stereotypic observation in those with the disorder, particularly
associated with the severe variant [48] (Preprint: Wan S et al. (2020)
Characteristics of lymphocyte subsets and cytokines in peripheral blood
of 123 hospitalized patients with 2019 novel coronavirus pneumonia
(NCP). medRxiv. DOI: https://doi.org/10.1101/2020.02.10.
20021832).
The pulmonary interstitium reveals a predominance of CD8+T cells,
a response considered to be crucial for SARS-CoV-2 clearance.
However, the concomitant presence of elevated levels of IL-6, and IL-8,
impair the ability of T cells to prime dendritic cells against the virus,
and also limit macrophage clearance of the pathogen. Similar to MERS,
also characterized by augmented circulating levels of IL-6, there is a
reduced production and elaboration of anti-viral cytokines, such as the
type I interferons (IFN alpha and beta) [67,68].
9. Conclusion
While the lung is the principal and most crucial target of attention
for those with severe COVID-19, the distribution of the ACE-2-r is suf-
ficiently wide that we are confronted with the controversy as to whe-
ther damage to the kidneys, GI tract, heart, skin, CNS, and PNS is a
consequence of the reduced oxygen-carrying capacity of blood, sec-
ondary to the damage to the lung's gas exchange apparatus, or whether
viral targeting of endothelium in other tissue beds can also foment the
PANIC Attack, and the resultant injury mechanisms associated with
such uncoordinated and poorly regulated immune activation.
The time is upon us to move urgently in order to identify ther-
apeutic strategies which can bring to bear the necessary diversity of
counterbalancing mechanisms commensurate with the wide spectrum
of activated inflammatory mechanisms triggered by SARS-CoV-2, and
which collectively represents the newly defined designation of PANIC
Attack, extensively characterized in this paper, and which we have
proposed to be directly responsible for the pathobiological under-
pinnings of the severe variant of COVID-19.
In Part II of our 2-part series on the COVID-19 pandemic, and the
corresponding global human crisis it has produced, we advance the
innovative hypothesis that the repurposed application of HDMTX-LR,
represents a particularly interesting candidate therapy, worthy of in-
vestigation within the context of a randomized controlled clinical trial.
This trial is needed to confirm or refute the contention that this WHO
designated essential treatment can uncouple the SARS-CoV-2 triggered
constellation of immune activities that compositionally represent the
highly injurious PANIC Attack, which leads to obliteration of the
bronchopulmonary alveolar gas-exchange apparatus, predisposing the
severe COVID-19 patient to disabling morbidity, and a significant risk
of mortality.
Methotrexate with leucovorin rescue is an FDA approved and gen-
eric treatment regimen, that is inexpensive, widely available, and one
with an extensive experiential track record of well-identified adverse
events and toxicities, while also being associated with a corresponding
and longstanding effective spectrum of risk mitigtation strategies. Most
importantly, HDMTX-LR represents a treatment strategy which is en-
dowed with an impressively broad heterogeneity of anti-inflammatory
properties spanning the human immune network, and which strikingly
align with each of the currently identified components of the newly
defined PANIC injury construct, fomented by the SARS-CoV-2 agent.
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